Rapport Therapeutics said Tuesday its investigational oral drug that dials down the effect of AMPA receptors has cleared a mid-stage trial in bipolar mania, paving …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.